Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27
September 20 2017 - 8:01AM
ZUG, Switzerland, Sept. 20, 2017 -- Auris Medical
Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to
developing therapeutics that address important unmet medical needs
in otolaryngology, today announced that Thomas Meyer, Ph.D.,
Chairman and Chief Executive Officer, will present at the LEERINK
Partners Rare Disease Roundtable Series in New York City on
Wednesday, September 27, 2017, at 9:30 a.m. Eastern Time. A live
webcast of the event will be available through the Events and
Presentations page in the Investors section of the Auris
Medical website at www.aurismedical.com, and a replay of
the presentation will be available following the event.About
Auris Medical
Auris Medical is a Swiss biopharmaceutical company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology. The company is focused on the Phase 3
development of treatments for acute inner ear hearing loss (AM-111)
and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of
intratympanic administration with biocompatible gel formulations.
In addition, Auris Medical is developing intranasal betahistine for
Meniere's disease and other vestibular disorders (AM-125) as well
as early-stage research and development projects. The Company was
founded in 2003 and is headquartered in Zug, Switzerland. The
shares of Auris Medical Holding AG trade on the NASDAQ Global
Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations
and Corporate Communications, +41 61 201 1350,
investors@aurismedical.com
Media contact: David Schull, Russo Partners,
1-858-717-2310,david.schull@russopartnersllc.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2023 to Apr 2024